PD‐L1‐negative non‐small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first‐line pembrolizumab plus chemotherapy: A case report and review the literature

BRAF mutations are uncommon in non‐small cell lung cancer (NSCLC), accounting for less than 5% of all NSCLC cases. The utilization of targeted therapies in non‐V600E BRAF mutant NSCLC is considered controversial, although non‐V600E genotype is reported in ~50% of all BRAF mutant patients. We documen...

Descripción completa

Detalles Bibliográficos
Autores principales: Do, Kien Hung, Nguyen, Tai Van, Nguyen Thi Bich, Phuong, Nguyen, Gia Hoang, Nguyen, Chu Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156919/
https://www.ncbi.nlm.nih.gov/pubmed/37151366
http://dx.doi.org/10.1002/rcr2.1155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156919/
https://www.ncbi.nlm.nih.gov/pubmed/37151366
http://dx.doi.org/10.1002/rcr2.1155

Ejemplares similares